Annual report
177A.TEDINET S100W2HI
Period2024-04-01 → 2025-03-31
Filed2025-06-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 134
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥4.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥4.7bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥991m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥597m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥636m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥918m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.0bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥636m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥795m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥385m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥830m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥588m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥795m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥385m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥9.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥6.6bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥5.6bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.3bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.0bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥2.2bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥916m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥824m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥461m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥763m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥577m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥575m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥83m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥172m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥360m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥157.57 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.43 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥199.23 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥173.5 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,131.12 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥802.5 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥724.57 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥532.27 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 63.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.7% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.2% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 17.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 31.7% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 31.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 167 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 159 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 139 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 130 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥4.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥4.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥4.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.3bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥727m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥445m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥703m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥409m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.1bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥842m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥666m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥661m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥423m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥509m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥212m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥751m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥564m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥685m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥6.0bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥5.8bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.2bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.0bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.5bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥100.93 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥50.9 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥180.37 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.59 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2,023.85 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥24 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥968.65 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥683.18 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥651.21 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥480.9 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,121.96 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 61.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.2% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.2% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 31.9% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 33.2% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 64.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,111,600 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,165,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,165,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 416,500 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 338,500 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 141 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 135 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 117 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 108 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 98 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥16m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥528m |
| Cell Process Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥130m |
| Cell Process Businessreportable segment | employees | at 2025-03-31 | 38 pure |
| Cell Process Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Cell Process Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.2bn |
| Cell Process Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥313m |
| Microbiological Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥131m |
| Microbiological Businessreportable segment | employees | at 2025-03-31 | 55 pure |
| Microbiological Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Microbiological Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Microbiological Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥441m |
| Tissue Culture Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥83m |
| Tissue Culture Businessreportable segment | employees | at 2025-03-31 | 60 pure |
| Tissue Culture Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.3bn |
| Tissue Culture Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥2.3bn |
| Tissue Culture Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥765m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥344m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥5.2bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥5.2bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥15m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥415m |
| Cell Process Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥114m |
| Cell Process Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Cell Process Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Cell Process Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥472m |
| Microbiological Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥100m |
| Microbiological Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Microbiological Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Microbiological Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥69m |
| Tissue Culture Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥69m |
| Tissue Culture Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Tissue Culture Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Tissue Culture Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥609m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥284m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Cell Process Businessreportable segment | employees | at 2025-03-31 | 38 pure |
| Microbiological Businessreportable segment | employees | at 2025-03-31 | 50 pure |
| Tissue Culture Businessreportable segment | employees | at 2025-03-31 | 39 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,440
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)小 林 雅 彦 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)筑 紫 徹 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)コージンバイオ株式会社の売上高の期間帰属の適切性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)注記事項「（連結財務諸表作成のための基本となる重要な事項）４．会計方針に関する事項(5)重要な収益及び費用の計上基準」 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)小 林 雅 彦 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)筑 紫 徹 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)売上高の期間帰属の適切性 | |
| Same as kam for consolidated fskam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior3YearDuration | 3947089000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 4742992000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 4770096000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 5206287000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 917837000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 1244391000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 635601000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 1065412000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 587675000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 829790000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 384978000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 794759000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 617245000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 842585000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 403698000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 843081000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant | 2216895000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant | 3017830000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 3342393000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant | 5781821000 | JPY |
| Total assets (5-year summary) | Prior3YearInstant | 5595281000 | JPY |
| Total assets (5-year summary) | Prior2YearInstant | 6134824000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 6589322000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant | 9066648000 | JPY |
| Net assets per share (5-year summary) | Prior3YearInstant | 532.27 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 724.57 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 802.50 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |